REG - Genedrive PLC - Scotland NHS “test of change” pilot programme

GenedriveAnnouncement

18/12/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251218:nRSR0225Ma&default-theme=true

RNS Number : 0225M  Genedrive PLC  18 December 2025

genedrive plc

("genedrive" or the "Company")

 

Genedrive's CYP2C19 ID kit piloted as a "test of change" in Scotland NHS
Grampian and Western Isles

 

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company,
announces that Genedrive's CYP2C19 ID Kit has been implemented into Scottish
NHS Grampian (Dr. Gray's Hospital, Elgin) & NHS Western Isles (Western
Isles Hospital, Stornoway) under a "test of change" pilot programme for stroke
patients in remote and rural settings.

 

Whilst the pathway for CYP2C19 genotyping in NHS Scotland currently relies on
laboratory testing, the Centre For Sustainable Delivery, commissioned by the
Scottish Government, are assessing the impact of rapid genetic testing using
the Genedrive CYP2C19 ID kit under a "test of change" programme which will run
for approximately one year and include c.400 patients.

 

Further details are available at https://shorturl.at/P4i00
(https://shorturl.at/P4i00)

 

 

Dr Gino Miele, CEO of genedrive plc, said: "We are delighted that the Centre
for Sustainable Delivery is assessing the impact of our interventional rapid
genetic test solution in NHS Grampian and Western Isles, enabling a precision
medicine approach to antiplatelet therapy in these stroke patients in rural
settings, and ultimately, significantly better outcomes for patients in these
communities.  Whilst a relatively small "pilot" programme, it is notable that
our interventional test is being explored as a "test of change" and we are
confident that the clinical value of our rapid testing solution will continue
to be evident and the case for wider deployment in Scotland strengthened."

 

NHS Grampian consultant in stroke/acute medicine and clinical lead for the
project, Petrus Elofuke, said: "We are introducing the Genedrive® CYP2C19 ID
Kit test as a test of change in Elgin and Stornoway at the same time as
samples are sent for lab-based testing. We'll look at how results compare over
the next year. It's the first time a device of this kind has been tested in
remote and rural settings, and we're extremely proud to be working with
colleagues across the two health boards as well as the national Centre for
Sustainable Delivery."

 

Clinical lead for the project in NHS Western Isles, David Rigby said: "If the
devices deliver proven results over the next year, then our project will
inform the business case for revolutionising stroke care for remote and rural
patients across Scotland. The Genedrive® devices are the size of a small shoe
box and are easily accommodated in smaller rural hospitals. We are very
pleased to be working closely alongside manufacturers Genedrive Diagnostics
Ltd and providing huge benefit to local patients as we make the case for wider
use of this exciting new tech."

 

Jason White the Head of Innovation in the Accelerated National Innovation
Adoption (ANIA) team which is part of the NHS National Centre for Sustainable
Delivery, said: "This project is a powerful example of how innovation can
directly improve patient care, especially in remote and rural communities. By
enabling rapid genetic testing at the point of care, we're helping clinicians
make faster, more informed decisions about stroke treatment. It's about
delivering the right care, in the right place, at the right time and we're
proud to support this collaborative effort through the ANIA pathway."

Engage with the genedrive management team directly by asking questions,
watching video
summaries and seeing what other shareholders have to say.
Navigate to our Interactive Investor
hub here:
https://investors.genedrive.com/link/PZ3d7y
(https://investors.genedrive.com/link/PZ3d7y)

 

For further information, please contact:

 

 Genedrive plc                                     https://investors.genedrive.com/s/e0025c

                                                 (https://investors.genedrive.com/s/e0025c)
 Dr Gino Miele (CEO)

                                                 +44 (0) 161 989 0245
 Russ Shaw (CFO)

 We encourage all investors to share questions

 on this announcement via our investor hub
 Peel Hunt LLP - Nominated Adviser, Joint Broker     +44 (0) 20 7148 8900

 James Steel
 Walbrook PR Ltd (Media & Investor Relations)      https://investors.genedrive.com/s/e0025c

                                                 (https://investors.genedrive.com/s/e0025c)
 Anna Dunphy

                                                   +44 (0)20 7933 8780 or genedrive@walbrookpr.com
                                                   (mailto:genedrive@walbrookpr.com)

                                                   +44 (0)7876 741 001

 

Subscribe to our news alert service: https://investors.genedrive.com/s/efea03
(https://investors.genedrive.com/s/efea03)

 

About genedrive plc (http://www.genedrive.com)

genedrive plc is a pharmacogenetic testing company developing and
commercialising a low cost, rapid, versatile and simple to use point of need
pharmacogenetic platform for the diagnosis of genetic variants. This helps
clinicians to quickly access key genetic information that will aid them make
the right choices over the right medicine or dosage to use for an effective
treatment, particularly important in time-critical emergency care healthcare
paradigms. Based in the UK, the Company is at the forefront of Point of Care
pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on
how your individual genetics impact a medicines ability to work for you.
Therefore, by using pharmacogenetics, medicine choices can be personalised,
made safer and more effective. The Company has launched its two flagship
products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit,
both developed and validated in collaboration with NHS partners and deployed
on its point of care thermocycler platform. Both tests are single-use
disposable cartridges which are ambient temperature stable, circumventing the
requirement for cold chain logistics. The Directors believe the Genedrive®
MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on
antibiotic use in neonatal intensive care units within 26 minutes, ensuring
vital care is delivered, avoiding adverse effects potentially otherwise
encountered and with no negative impact on the patient care pathway. Its
CYP2C19 ID Kit which has no comparably positioned competitor currently allows
clinicians to make a decision on the use of Clopidogrel in stroke patients in
70 minutes, ensuring that patients who are unlikely to benefit from or suffer
adverse effects from Clopidogrel receive an alternative antiplatelet
therapeutic in a timely manner, ultimately improving outcomes. Both tests have
undergone review by the National Institute for Health and Care Clinical
Excellence ("NICE") and have been recommended for use in the UK NHS. The
Company has a clear commercial strategy focused on accelerating growth through
maximising in-market sales, geographic and portfolio expansion and strategic
M&A, and operates out of its facilities in Manchester.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEANAXFDPSFFA



            Copyright 2019 Regulatory News Service, all rights reserved